Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Frontline Maintenance Niraparib Takes Step Toward EU Approval in Ovarian Cancer

February 27th 2020

The European Medicines Agency has validated a Type II Variation for niraparib as a first-line maintenance treatment for patients with advanced ovarian cancer who have responded to platinum-based chemotherapy, regardless of biomarker status.

Modern Surgical and Staging Techniques Coming to Forefront of Endometrial Cancer

February 27th 2020

Ian S. Hagemann, MD, PhD, discusses identifying resectable lymph nodes via ultrastaging and the importance of multidisciplinary treatment in patients with endometrial cancer.

Dr. Penson on the Eligibility Criteria for PARP Inhibitors in Advanced Ovarian Cancer

February 26th 2020

Richard T. Penson, MD, MRCP, associate professor of medicine, Harvard Medical School, and clinical director of Medical Gynecologic Oncology, in the Department of Medicine, Massachusetts General Hospital, discusses the eligibility criteria for PARP inhibitors in advanced ovarian cancer.

Dr. Hoffman on Research Regarding Neoadjuvant Chemo and Primary Debulking in Ovarian Cancer

February 26th 2020

Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses ongoing research regarding neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian cancer.

Dr. Wenham on Trials Evaluating IP, IV, and Dose-Dense Chemotherapy in Ovarian Cancer

February 26th 2020

Robert M. Wenham, MD, gynecologic oncologist and chair of the Gynecologic Oncology Program at Moffitt Cancer Center, discusses data with intraperitoneal (IP) chemotherapy, dose-dense chemotherapy, and intravenous (IV) chemotherapy in patients with advanced ovarian cancer.

Dr. Copeland on the Prevalence of Ovarian Cancer in the United States

February 25th 2020

Larry J. Copeland, MD, discusses the prevalence of ovarian cancer in the United States.

Dr. Comerci on the Utility of Primary Debulking Surgery in Ovarian Cancer

February 25th 2020

John T. Comerci, MD, discusses the utility of primary debulking surgery in ovarian cancer.

Minimally Invasive Hysterectomy Shows Inferior Recurrence Rates in Early-Stage Cervical Cancer

February 24th 2020

Patients with early-stage cervical cancer who undergo minimally invasive radical hysterectomy have an inferior rate of disease-free survival compared to women who undergo open abdominal radical hysterectomy.

FDA Accepts Niraparib Application for Frontline Maintenance in Ovarian Cancer

February 24th 2020

The FDA has accepted a supplemental New Drug Application for niraparib for use as a frontline maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status.

Adjuvant Ipilimumab Shows Early Activity in Advanced Cervical Cancer

February 21st 2020

Immune checkpoint blockade with ipilimumab, combined with radiation therapy, is tolerable and effective in patients with node-positive, stage Ib2 to IV cervical cancer.

Dr. Emens on Combining Checkpoint Inhibitors With PARP Inhibitors in Ovarian Cancer

February 21st 2020

Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.

Dr. Chon on Challenges With Maintenance Therapy in Ovarian Cancer

February 20th 2020

Hye Sook Chon, MD, gynecologic oncologist, Moffitt Cancer Center, discusses challenges that are still faced in the maintenance setting in advanced ovarian cancer.

Dr. Penson on Biomarkers of Response to PARP Inhibitors in Ovarian Cancer

February 20th 2020

Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Medicine, Massachusetts General Hospital, discusses prospective biomarkers that may predict response to PARP inhibitors in advanced ovarian cancer.

Dr. Hoffman on Primary Debulking Versus Neoadjuvant Chemotherapy in Ovarian Cancer

February 20th 2020

Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses eligibility criteria for primary debulking surgery versus neoadjuvant chemotherapy in advanced ovarian cancer.

If Only That Phase III Oncology Trial Had Been Designed Differently

February 19th 2020

The cancer treatment community's ultimate perception of a successfully completed phase III randomized trial depends in large part on how well the trial was conceived and structured. To permit adequate accrual in a timely manner and optimize the chances for a study to achieve success, the question it poses must be relevant to ensure interest by clinical investigators, referring clinicians, and potential research subjects. Further, the initiative must have adequate funding for data collection and analysis, translational laboratory investigations, and other trial components.

Dr. Fowler on Patient Eligibility for Cytoreductive Surgery in Ovarian Cancer

February 19th 2020

Jeffrey M. Fowler, MD, discusses patient eligibility for cytoreductive surgery in newly diagnosed ovarian cancer.

Dr. Wenham on Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in Ovarian Cancer

February 19th 2020

Robert M. Wenham, MD, gynecologic oncologist and chair of the Department of Gynecologic Oncology at Moffitt Cancer Center, sheds light on the debate between neoadjuvant chemotherapy and primary debulking surgery in patients with newly diagnosed, advanced ovarian cancer.

Somatic Testing Could Be Standard Approach in Endometrial Cancer

February 18th 2020

Julia Fehniger, MD, discusses emerging strategies in the treatment paradigm for patients with BRCA1/2-mutant endometrial cancer.

Niraparib Plus Radiotherapy Explored in Metastatic Cervical Cancer

February 18th 2020

Investigators are exploring concurrent PARP inhibition and definitive regional radiotherapy in patients with metastatic invasive cervical cancer in an ongoing phase I/II study.

Dr. Moore on Results of the FORWARD I/GOG 3011 Trial in Ovarian Cancer

February 14th 2020

Kathleen Moore, MD, discusses topline findings from the phase III FORWARD I/GOG 3011 trial in ovarian cancer.

x